UP-TO-DATE, RESEARCH BASED INFORMATION ABOUT PSYCHEDELICS.
Examining associations between MDMA/ecstasy and classic psychedelic use and impairments in social functioning in a U.S. adult sample
Lifetime MDMA/ecstasy use was associated with lowered odds of three of our four social impairment outcomes.
Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics
This study examined the prevalence and associations of challenging, difficult, or distressing experiences using classic psychedelics.
Therapeutic effect of psilocybin in addiction: A systematic review
Larger RCTs in patients with SUDs need to evaluate whether psilocybin-assisted therapy is effective in patients with SUD.
Experts' mixed responses to the surprise announcement of psilocybin & MDMA becoming (limitedly) licensed in Australia
The Australian Therapeutic Goods Administration has announced that psilocybin for treatment-resistant depression and MDMA for PTSD will be legally prescribable.
Reduced death anxiety as a mediator of the relationship between acute subjective effects of psychedelics and improved subjective well-being
The findings are consistent with the hypothesis that some of the benefits of psychedelic-induced mystical experiences on subjective well-being may emerge due to reductions in death anxiety.
Australia becomes first country to recognise psychedelics as medicines
In a surprising move, Australia’s Therapeutic Goods Administration (TGA) has announced that it will permit the prescribing of MDMA and Psilocybin from the 1st of July.
“After the Ecstasy, the Laundry” – Shayla Love’s take on psychedelics in 2022 – Psychedelic Alpha
Themes that shaped the psychedelics space in 2022, plus her hopes and predictions for the coming year.
Psilocybin-assisted therapy improves psycho-social-spiritual well-being in cancer patients
Findings suggest that psilocybin-assisted therapy facilitates psycho-social-spiritual growth as measured by the NIH-HEALS and its three factors.
Lasting increases in trait mindfulness after psilocybin correlate positively with the mystical-type experience in healthy individuals
We here show that lasting changes in trait mindfulness following psilocybin administration are positively associated with intensity of the mystical-type experience.
Small Pharma reports positive top-line results from phase IIa trial of SPL026 in major depressive disorder
intravenous N,N-Dimethyltryptamine (“DMT”), with supportive therapy for the treatment of MDD met the primary endpoint in its Phase IIa clinical trial.
Psychedelic integration challenges: Participant experiences after a psilocybin truffle retreat in the Netherlands
We discuss the implications for psychedelic integration and harm reduction practices and for future psychedelic research.
Psychedelics for patients with cancer: A comprehensive literature review
Psychedelics have a unique mechanism of action that might be well suited for treating anxiety and depression associated with cancer.
Is the high cost of psychedelic therapy worth it?
In this column I will examine the costs and benefits of psychedelic-assisted therapy,
Could ketamine-assisted therapy help treat alcohol disorder?
A new £2.4 million phase III trial delivered through seven NHS sites across the UK will investigate whether ketamine-assisted therapy could help treat alcohol disorder.
Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness
Results suggest that experience with psilocybin is the only reliable (and strongest) predictor of Nature Relatedness.